The Manufacturers Life Insurance Company Invests $2.93 Million in Celcuity, Inc. $CELC

The Manufacturers Life Insurance Company bought a new position in Celcuity, Inc. (NASDAQ:CELC) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 27,977 shares of the company’s stock, valued at approximately $2,927,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CELC. EverSource Wealth Advisors LLC grew its position in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares during the period. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the period. Parallel Advisors LLC purchased a new position in shares of Celcuity in the 1st quarter worth about $38,000. Finally, Meeder Asset Management Inc. acquired a new position in shares of Celcuity in the 4th quarter valued at about $42,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $155.00 target price on shares of Celcuity in a report on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Monday, August 17th. Leerink Partners set a $155.00 price objective on shares of Celcuity in a research note on Tuesday, June 2nd. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Stock Up 3.3%

CELC stock opened at $91.98 on Wednesday. Celcuity, Inc. has a twelve month low of $44.42 and a twelve month high of $151.02. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.50 billion, a P/E ratio of -21.39 and a beta of 0.21. The firm has a 50 day simple moving average of $94.66 and a 200-day simple moving average of $106.96.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, equities research analysts predict that Celcuity, Inc. will post -4.75 earnings per share for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.